ArticleJournal of clinical and translational hepatology2026
Neu5Gc-associated Serum Immunoglobulin G Glycosylation as a Diagnostic Biomarker for Hepatocellular Carcinoma.
Article in Journal of clinical and translational hepatology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background and Aims: Given the lack of efficient biomarkers for hepatocellular carcinoma (HCC) diagnosis, this study aimed to develop an HCC diagnostic strategy based on serum protein glycosylation signatures. We characterized differential N-glycosylation patterns of serum IgG to differentiate HCC from healthy controls and liver cirrhosis, and elucidated the molecular mechanisms driving aberrant Neu5Gc elevation in HCC to provide a theoretical basis for clinical application and differential diagnosis of HCC. Methods: LIP-ELISA was applied to quantify serum Neu5Gc in 6,768 healthy individuals for baseline establishment. IgG was purified and subsequently analyzed by RPLC-MS/MS for glycosylation profiling in HCC and healthy samples. Bioinformatic analysis of Results: In a cohort of 1,114 participants, the LIP-ELISA platform achieved 80.21% sensitivity, 96.01% specificity, and 92.46% accuracy for primary HCC diagnosis. Serum IgG from HCC patients displayed multi-branched N-glycans modified with core fucose and Neu5Gc. Key molecules involved in glycan modification were identified, enabling the development of multiplexed gene detection for HCC, LC, and chronic hepatitis B. Conclusions: This study established an LIP-ELISA-based clinical diagnostic platform combining AFP and Neu5Gc, defined sialic acid-modified glycan structures, and preliminarily identified regulators of Neu5Gc biosynthesis, providing novel insights for HCC diagnosis and mechanism research.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.